Cipla Readies gSymbicort, Semaglutide Amid Sale Speculation ‘Distraction’

"Very small investment” in gene editing/sequencing on cards

Cipla’s US business scales new peak in Q2 amid strong showing overall even as the promoter group stake sale speculation is becoming a 'distraction'. The company has new peptide assets, among others, in the wings while management also points to traction in the 'mRNA journey'.

New revenue peaks at Cipla • Source: Shutterstock

Cipla Limited delivered a strong set of numbers in the second quarter of fiscal 2024 and also outlined pipeline promise, though uncertainty and ongoing speculation around a potential stake sale by the promoter group may be fueling some “distraction” across the ranks. (see side box)

More from Business

More from Scrip